Imalumab

Imalumab (BAX69) is a monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth.[1][2] Phase I studies were completed in early 2016,[3] and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer.[4] It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals.[5]

A phase I/II trial in patients with malignant ascites was terminated in 2016.[6]

References

  1. ↑ http://mct.aacrjournals.org/content/14/12_Supplement_2/A153
  2. ↑ https://www.clinicaltrials.gov/ct2/show/NCT02448810
  3. ↑ https://clinicaltrials.gov/show/NCT01765790
  4. ↑ https://www.clinicaltrials.gov/ct2/show/NCT02448810
  5. ↑ http://adisinsight.springer.com/drugs/800010225
  6. ↑ http://adisinsight.springer.com/drugs/800010225
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.